Drug | Drug type | Details | Subtype | ClinicalTrails.gov identifier |
---|---|---|---|---|
GNbAc1 | Monoclonal antibody | Assess the efficacy of HERV-W Env antagonist in MS | RRMS | NCT02782858 |
GSK239512 | Histamine H, receptor antagonist | Evaluate whether it can remyelinate lesions in patients | RRMS | NCT01772199 |
Opicinumab (BIIB033) | Anti-lingo-1 monoclonal antibody | Efficacy, safety and dose tolerability for CNS remyelination | RRMS | NCT01864148 |
Domperidone | Dopamine D2 antagonist | Study myelin repair in patients with enhancing lesion by MRI | RRMS | NCT02493049 |
Clemastine Fumarate | Antihistaminic | Assessment of its tolerability as a remyelinating agent | RRMS | NCT02040298 |
Vaginal estriol | Estrogen | Evaluate the efficiency and remyelination role in female patients with urogenital symptoms | RRMS | NCT03774407 |
Liothyronine | Thyroid hormone | Safety and dose finding study of remyelination | RRMS, SPMS, PPMS | NCT02760056 |
Olesoxime | Cholesterol-like neuroprotectant | Measurement of remyelination by MRI | RRMS | NCT01808885 |
Natalizumab | Anti-integrin monoclonal antibody | Evaluate the remyelination capacity | RRMS | NCT00937677 |
Quetiapine fumarate | Atypical Antipsychotic | Safety and tolerability of this remyelinating agent in patients | RRMS, RPMS | NCT02087631 |
Alemtuzumab | Anti-CD52 monoclonal antibody | MRI measurement of remyelination | RRMS | NCT01395316 |
Adrenocorticotropic hormone (ACTH) | Hormone | Evaluate the effect of ACTH for treating demyelination in patients | RRMS, SPMS | NCT00854750 |
Bazedoxifene acetate | Selective estrogen receptor modulator | Test the efficacy of the drug as a remyelinating agent | RRMS | NCT04002934 |